Fiber in diabetes: separate glucose trials from survival cohorts
One review combined two evidence streams that answer different questions about higher fiber intake.

Illustrative food image, not a photograph of the study intervention.
Two evidence streams, not one experiment
Reynolds and colleagues reviewed higher fibre intake in adults with prediabetes or diabetes, separating prospective cohort evidence from controlled trials. They identified two multicountry cohorts involving 8,300 adults with type 1 or type 2 diabetes, followed for an average of 8.8 years. They also identified 42 trials involving 1,789 adults with prediabetes, type 1 diabetes or type 2 diabetes. The review sought higher-fibre comparisons without additional dietary or other lifestyle modification. This scope differs from a whole-diet programme: its central question concerned increasing fibre intake. It also means the results are not limited to one diabetes type or a single plant-based menu.
Reynolds AN, Akerman AP, Mann J. PLoS medicine, 2020. PMID 32142510 · DOI
The glucose results have their own units
Across 33 trials, higher fibre intake reduced HbA1c by a mean 2.00 mmol/mol compared with lower-fibre diets; the 95% confidence interval ran from a reduction of 3.30 to 0.71 mmol/mol. Across 34 trials, fasting plasma glucose fell by a mean 0.56 mmol/L, with an interval of 0.73 to 0.38 mmol/L lower. These are two separately pooled outcomes with different units and different contributing trial counts. The HbA1c result is not a reduction of two percentage points. Keeping the original units visible avoids overstating the glycaemic effect and preserves what the abstract actually reports about these controlled comparisons.
Reynolds AN, Akerman AP, Mann J. PLoS medicine, 2020. PMID 32142510 · DOI
Survival was an observational finding
The cohort analysis associated an intake of 35 g of fibre daily, compared with an average intake of 19 g, with 14 fewer deaths per 1,000 participants over the study duration. The 95% confidence interval was four to 19 fewer deaths. These numbers came from prospective cohort data, not from a trial randomising participants to those fibre targets and observing survival. They should therefore not be presented as a guaranteed mortality reduction from adding a specified quantity of fibre. The distinction is especially important in a review that also contains controlled glucose trials: evidence for an intermediate outcome does not convert a separate survival association into an experimental result.
Reynolds AN, Akerman AP, Mann J. PLoS medicine, 2020. PMID 32142510 · DOI
Heterogeneity and duration temper the message
All trial analyses were subject to high heterogeneity. Baseline fibre intake, global region and participant inclusion criteria beyond diabetes type influenced the pooled findings. The authors also identified a lack of controlled trials lasting at least 12 months and a lack of prospective cohort data from non-European countries. They reported greater glycaemic improvements among people moving from low to moderate or high fibre intakes. Together, these details favour a measured interpretation: the review supports improvements in glycaemic measures with higher fibre intake, but its average results do not predict the response to one recipe, establish long-term trial outcomes or remove differences between the populations studied.
Reynolds AN, Akerman AP, Mann J. PLoS medicine, 2020. PMID 32142510 · DOI